Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

June 10, 2021

Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

Sapreme’s SPT001 compound significantly improves intracellular release of targeted antisense oligonucleotides (ASO’s) and thereby also their therapeutic efficacy. In addition to oligonucleotides, SPT001 has also been demonstrated to enhance delivery of other targeted payloads such as antibody-conjugated toxins.

The presentation and Q&A session will be hosted on June 17th 2021 via the summit’s virtual stage and platform.

Home > News > Sapreme will present data at the RNAi-Based The...

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds